
Palmer Taylor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3870919/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interactions of Nereistoxin and Its Analogs with Vertebrate Nicotinic Acetylcholine Receptors and Molluscan ACh Binding Proteins. Marine Drugs, 2022, 20, 49.	2.2	5
2	Ligand design for human acetylcholinesterase and nicotinic acetylcholine receptors, extending beyond the conventional and canonical. Journal of Neurochemistry, 2021, 158, 1217-1222.	2.1	5
3	Enhancing Target Tissue Levels and Diminishing Plasma Clearance of Ionizing Zwitterionic Antidotes in Organophosphate Exposures. Journal of Pharmacology and Experimental Therapeutics, 2021, 378, 315-321.	1.3	2
4	Covalent inhibition of hAChE by organophosphates causes homodimer dissociation through long-range allosteric effects. Journal of Biological Chemistry, 2021, 297, 101007.	1.6	8
5	Cholinergic Capsules and Academic Admonitions. Annual Review of Pharmacology and Toxicology, 2021, 61, 25-46.	4.2	2
6	Evaluation of high-affinity phenyltetrahydroisoquinoline aldoximes, linked through anti-triazoles, as reactivators of phosphylated cholinesterases. Toxicology Letters, 2020, 321, 83-89.	0.4	13
7	Lessons from nature: Structural studies and drug design driven by a homologous surrogate from invertebrates, AChBP. Neuropharmacology, 2020, 179, 108108.	2.0	9
8	Rational design, synthesis, and evaluation of uncharged, "smart―bis-oxime antidotes of organophosphate-inhibited human acetylcholinesterase. Journal of Biological Chemistry, 2020, 295, 4079-4092.	1.6	24
9	Drysdalin, a snake neurotoxin with higher affinity for soluble acetylcholine binding protein from Aplysia californica than from Lymnaea stagnalis. Toxicon, 2020, 187, 86-92.	0.8	Ο
10	Adhesion, Catalysis and Signaling: A Commonality of Association Followed by Distinctive Events Driving Function. Structure, 2019, 27, 1055-1056.	1.6	0
11	Synthesis, Pharmacological Characterization, and Structure–Activity Relationships of Noncanonical Selective Agonists for I±7 nAChRs. Journal of Medicinal Chemistry, 2019, 62, 10376-10390.	2.9	12
12	A new crystal form of human acetylcholinesterase for exploratory room-temperature crystallography studies. Chemico-Biological Interactions, 2019, 309, 108698.	1.7	82
13	Productive reorientation of a bound oxime reactivator revealed in room temperature X-ray structures of native and VX-inhibited human acetylcholinesterase. Journal of Biological Chemistry, 2019, 294, 10607-10618.	1.6	13
14	Assessment of ionizable, zwitterionic oximes as reactivating antidotal agents for organophosphate exposure. Chemico-Biological Interactions, 2019, 308, 194-197.	1.7	18
15	Counteracting tabun inhibition by reactivation by pyridinium aldoximes that interact with active center gorge mutants of acetylcholinesterase. Toxicology and Applied Pharmacology, 2019, 372, 40-46.	1.3	8
16	Reversal of Tabun Toxicity Enabled by a Triazoleâ€Annulated Oxime Library—Reactivators of Acetylcholinesterase. Chemistry - A European Journal, 2019, 25, 4100-4114.	1.7	24
17	Structureâ€Activity Relationships of Selective Pyrimidine Agonists on α7â€nAChRs. FASEB Journal, 2019, 33, 667.9.	0.2	0
18	Planarian cholinesterase: molecular and functional characterization of an evolutionarily ancient enzyme to study organophosphorus pesticide toxicity. Archives of Toxicology, 2018, 92, 1161-1176.	1.9	30

#	Article	IF	CITATIONS
19	Post-exposure treatment with the oxime RS194B rapidly reactivates and reverses advanced symptoms of lethal inhaled paraoxon in macaques. Toxicology Letters, 2018, 293, 229-234.	0.4	30
20	Pharmacology, Pharmacokinetics, and Tissue Disposition of Zwitterionic Hydroxyiminoacetamido Alkylamines as Reactivating Antidotes for Organophosphate Exposure. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 363-372.	1.3	35
21	The Effect of Organophosphate (OP)â€Induced Structural Changes in Acetylcholinesterase on Kinetics of OP Inhibition and Oxime Reactivation. FASEB Journal, 2018, 32, 526.40.	0.2	0
22	Impact of Organophosphate (OP) Conjugation on Structure and Dynamics of Human Acetylcholinesterase. FASEB Journal, 2018, 32, 527.8.	0.2	0
23	Dynamics of Organophosphateâ€Induced Structural Changes in Acetylcholinesterase Revealed by Timeâ€Resolved Smallâ€Angle Xâ€Ray Scattering and Inelastic Neutron Scattering. FASEB Journal, 2018, 32, 527.7.	0.2	0
24	Bloodâ€brain Barrier Penetrant and Orally Bioavailable Antidotes to Organophosphate Poisoning. FASEB Journal, 2018, 32, 688.4.	0.2	0
25	Butyrylcholinesterase identification in a phenylvalerate esterase-enriched fraction sensitive to low mipafox concentrations in chicken brain. Archives of Toxicology, 2017, 91, 909-919.	1.9	7
26	Mechanistic studies of new oximes reactivators of human butyryl cholinesterase inhibited by cyclosarin and sarin. Journal of Biomolecular Structure and Dynamics, 2017, 35, 1272-1282.	2.0	22
27	Substituted 2-Aminopyrimidines Selective for α7-Nicotinic Acetylcholine Receptor Activation and Association with Acetylcholine Binding Proteins. Journal of the American Chemical Society, 2017, 139, 3676-3684.	6.6	15
28	Cyclic imine toxins from dinoflagellates: a growing family of potent antagonists of the nicotinic acetylcholine receptors. Journal of Neurochemistry, 2017, 142, 41-51.	2.1	59
29	Planarian cholinesterase: in vitro characterization of an evolutionarily ancient enzyme to study organophosphorus pesticide toxicity and reactivation. Archives of Toxicology, 2017, 91, 2837-2847.	1.9	38
30	Post-exposure treatment with the oxime RS194B rapidly reverses early and advanced symptoms in macaques exposed to sarin vapor. Chemico-Biological Interactions, 2017, 274, 50-57.	1.7	34
31	HI-6 assisted catalytic scavenging of VX by acetylcholinesterase choline binding site mutants. Chemico-Biological Interactions, 2016, 259, 148-153.	1.7	20
32	Limitations in current acetylcholinesterase structure–based design of oxime antidotes for organophosphate poisoning. Annals of the New York Academy of Sciences, 2016, 1378, 41-49.	1.8	17
33	Design and Synthesis of Nicotinic Acetylcholine Receptor Antagonists and their Effect on Cognitive Impairment. Chemical Biology and Drug Design, 2016, 87, 39-56.	1.5	7
34	Steric and Dynamic Parameters Influencing In Situ Cycloadditions to Form Triazole Inhibitors with Crystalline Acetylcholinesterase. Journal of the American Chemical Society, 2016, 138, 1611-1621.	6.6	30
35	Selectivity Optimization of Substituted 1,2,3-Triazoles as α7 Nicotinic Acetylcholine Receptor Agonists. ACS Chemical Neuroscience, 2015, 6, 1317-1330.	1.7	27
36	Cognitive Improvements in a Mouse Model with Substituted 1,2,3-Triazole Agonists for Nicotinic Acetylcholine Receptors. ACS Chemical Neuroscience, 2015, 6, 1331-1340.	1.7	13

#	Article	IF	CITATIONS
37	Mechanisms of Inhibition and Potentiation of α4β2 Nicotinic Acetylcholine Receptors by Members of the Ly6 Protein Family. Journal of Biological Chemistry, 2015, 290, 24509-24518.	1.6	40
38	Quaternary and tertiary aldoxime antidotes for organophosphate exposure in a zebrafish model system. Toxicology and Applied Pharmacology, 2015, 284, 197-203.	1.3	11
39	Marine Macrocyclic Imines, Pinnatoxins A and G: Structural Determinants and Functional Properties to Distinguish Neuronal α7 from Muscle α12βγδnAChRs. Structure, 2015, 23, 1106-1115.	1.6	42
40	Catalytic Soman Scavenging by the Y337A/F338A Acetylcholinesterase Mutant Assisted with Novel Site-Directed Aldoximes. Chemical Research in Toxicology, 2015, 28, 1036-1044.	1.7	41
41	Structural basis for cooperative interactions of substituted 2-aminopyrimidines with the acetylcholine binding protein. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10749-10754.	3.3	18
42	Imidazole Aldoximes Effective in Assisting Butyrylcholinesterase Catalysis of Organophosphate Detoxification. Journal of Medicinal Chemistry, 2014, 57, 1378-1389.	2.9	73
43	Multi-detection method for five common microalgal toxins based on the use of microspheres coupled to a flow-cytometry system. Analytica Chimica Acta, 2014, 850, 57-64.	2.6	25
44	Derivatives of 1,2,3â€ŧriazole lead found to be selective and potent agonists at the α7 nicotinic acetylcholine receptor (1059.8). FASEB Journal, 2014, 28, 1059.8.	0.2	0
45	Centrally acting oximes in reactivation of tabun-phosphoramidated AChE. Chemico-Biological Interactions, 2013, 203, 77-80.	1.7	64
46	Cholinesterase confabs and cousins: Approaching forty years. Chemico-Biological Interactions, 2013, 203, 10-13.	1.7	7
47	Mechanism of interaction of novel uncharged, centrally active reactivators with OP-hAChE conjugates. Chemico-Biological Interactions, 2013, 203, 67-71.	1.7	30
48	Catalytic detoxification of nerve agent and pesticide organophosphates by butyrylcholinesterase assisted with non-pyridinium oximes. Biochemical Journal, 2013, 450, 231-242.	1.7	73
49	Structureâ€Activity Considerations for Heteroaromatic nortropeines and Nâ€methyltropeines with Nicotinic Acetylcholine Receptor (nAChR) Subtypes and a Serotonin Receptor (5HT3A). FASEB Journal, 2013, 27, .	0.2	Ο
50	Structureâ€activity Relationships of Bicyclic Amine Heterocycles with α7 Nicotinic Acetylcholine Receptors (nAChR) and Related Ligandâ€gated Ion Channels. FASEB Journal, 2013, 27, lb554.	0.2	0
51	Processing of Cholinesterase-like α/β-Hydrolase Fold Proteins: Alterations Associated with Congenital Disorders. Protein and Peptide Letters, 2012, 19, 173-179.	0.4	8
52	Generation of Candidate Ligands for Nicotinic Acetylcholine Receptors via in situ Click Chemistry with a Soluble Acetylcholine Binding Protein Template. Journal of the American Chemical Society, 2012, 134, 6732-6740.	6.6	79
53	Synthesis of Selective Agonists for the α7 Nicotinic Acetylcholine Receptor with In Situ Click-Chemistry on Acetylcholine-Binding Protein Templates. Molecular Pharmacology, 2012, 82, 687-699.	1.0	17
54	Refinement of Structural Leads for Centrally Acting Oxime Reactivators of Phosphylated Cholinesterases. Journal of Biological Chemistry, 2012, 287, 11798-11809.	1.6	97

#	Article	IF	CITATIONS
55	The role of the β9–10 linker in nicotinic acetylcholine receptor selectivity. FASEB Journal, 2012, 26, lb579.	0.2	0
56	Generation of selective ligands for nicotinic acetylcholine receptors. FASEB Journal, 2012, 26, .	0.2	0
57	Molecular Determinants of Reactivation Potency for Novel, Efficacious, Centrally Active Oxime Reactivators of Phosphylated Acetylcholinesterase. FASEB Journal, 2012, 26, 851.5.	0.2	0
58	Characterizing Ligand-Gated Ion Channel Receptors with Genetically Encoded Ca++ Sensors. PLoS ONE, 2011, 6, e16519.	1.1	35
59	The Crystal Structure of the α-Neurexin-1 Extracellular Region Reveals a Hinge Point for Mediating Synaptic Adhesion and Function. Structure, 2011, 19, 767-778.	1.6	56
60	Oxime-assisted Acetylcholinesterase Catalytic Scavengers of Organophosphates That Resist Aging. Journal of Biological Chemistry, 2011, 286, 29718-29724.	1.6	49
61	New Structural Scaffolds for Centrally Acting Oxime Reactivators of Phosphylated Cholinesterases. Journal of Biological Chemistry, 2011, 286, 19422-19430.	1.6	110
62	Creating an α7 Nicotinic Acetylcholine Recognition Domain from the Acetylcholine-binding Protein. Journal of Biological Chemistry, 2011, 286, 42555-42565.	1.6	60
63	Investigating the structural influence of surface mutations on acetylcholinesterase inhibition by organophosphorus compounds and oxime reactivation. Chemico-Biological Interactions, 2010, 187, 238-240.	1.7	5
64	Interaction kinetics of oximes with native, phosphylated and aged human acetylcholinesterase. Chemico-Biological Interactions, 2010, 187, 163-166.	1.7	24
65	From Split to Sibenik: The tortuous pathway in the cholinesterase field. Chemico-Biological Interactions, 2010, 187, 3-9.	1.7	1
66	Structural insights into the exquisite selectivity of neurexin/neuroligin synaptic interactions. EMBO Journal, 2010, 29, 2461-2471.	3.5	38
67	An in vivo biosensor for neurotransmitter release and in situ receptor activity. Nature Neuroscience, 2010, 13, 127-132.	7.1	110
68	Defining the determinants of nicotine selectivity. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13195-13196.	3.3	1
69	Structural determinants in phycotoxins and AChBP conferring high affinity binding and nicotinic AChR antagonism. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6076-6081.	3.3	156
70	Cis and Trans Actions of the Cholinesterase-like Domain within the Thyroglobulin Dimer. Journal of Biological Chemistry, 2010, 285, 17564-17573.	1.6	26
71	Neuroligin Trafficking Deficiencies Arising from Mutations in the α/β-Hydrolase Fold Protein Family. Journal of Biological Chemistry, 2010, 285, 28674-28682.	1.6	40
72	Ligand design for human nicotinic acetylcholine receptors using in situ freezeâ€frame click chemistry. FASEB Journal, 2010, 24, 579.2.	0.2	0

#	Article	IF	CITATIONS
73	Validating the Acetylcholine Binding Protein's Conversion Potential to a Human Nicotinic Acetylcholine Receptor FASEB Journal, 2010, 24, 579.1.	0.2	0
74	Design of Novel Oxime Reactivators and Direct Characterization of Their Interaction With OP hE Conjugates. FASEB Journal, 2010, 24, 763.10.	0.2	0
75	Crystallographic comparison of nicotinic ligands in complex with the acetylcholine binding protein. FASEB Journal, 2010, 24, 579.4.	0.2	0
76	Biochemical characterization of the cellular biosynthesis and trafficking of Caspr2. FASEB Journal, 2010, 24, 839.1.	0.2	0
77	Targeting of Acetylcholinesterase in Neurons In Vivo: A Dual Processing Function for the Proline-Rich Membrane Anchor Subunit and the Attachment Domain on the Catalytic Subunit. Journal of Neuroscience, 2009, 29, 4519-4530.	1.7	58
78	Structural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal α7 nicotinic acetylcholine receptor. EMBO Journal, 2009, 28, 3040-3051.	3.5	153
79	A virtual screening study of the acetylcholine binding protein using a relaxed–complex approach. Computational Biology and Chemistry, 2009, 33, 160-170.	1.1	32
80	LRRTM2 Interacts with Neurexin1 and Regulates Excitatory Synapse Formation. Neuron, 2009, 64, 799-806.	3.8	338
81	Alphaâ€7 Nicotinic Acetylcholine Receptor (nAChR) Characteristics on the Acetylcholine Binding Protein. FASEB Journal, 2009, 23, 942.4.	0.2	0
82	A structureâ€guided design strategy to develop ligands with subtype selectivity for human nicotinic acetylcholine receptors. FASEB Journal, 2009, 23, 756.14.	0.2	0
83	Acetylcholinesterase Expression in Muscle Is Specifically Controlled by a Promoter-Selective Enhancesome in the First Intron. Journal of Neuroscience, 2008, 28, 2459-2470.	1.7	26
84	Freezeâ€Frame Clickâ€Chemistry Synthesis on a Soluble Alphaâ€7 Nicotinic Acetylcholine Receptor (nAChR) Ligand Binding Domain. FASEB Journal, 2008, 22, 1127.5.	0.2	0
85	In vitro screening of acetylcholinesterase reactivating potency and oxime assisted organophosphate hydrolysis for a library of novel oxime reactivators synthesized by "click hemistryâ€. FASEB Journal, 2008, 22, 717.7.	0.2	0
86	Investigating naturally occurring variations in the Acetylcholinesterase gene of a human population. FASEB Journal, 2008, 22, 1134.2.	0.2	0
87	Small angle xâ€ray scattering and analytical ultracentrifugation characterization of the extracellular domain of αâ€neurexin, alone and in complex with neuroliginâ€1. FASEB Journal, 2008, 22, 823.19.	0.2	0
88	Mapping the elusive neonicotinoid binding site. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 9075-9080.	3.3	74
89	Structural Analysis of the Synaptic Protein Neuroligin and Its Î ² -Neurexin Complex: Determinants for Folding and Cell Adhesion. Neuron, 2007, 56, 979-991.	3.8	142
90	Galanthamine and Non-competitive Inhibitor Binding to ACh-binding Protein: Evidence for a Binding Site on Non-α-subunit Interfaces of Heteromeric Neuronal Nicotinic Receptors. Journal of Molecular Biology, 2007, 369, 895-901.	2.0	111

#	Article	IF	CITATIONS
91	Protein Folding Determinants: Structural Features Determining Alternative Disulfide Pairing in α- and χ/λ-Conotoxinsâ€,‡. Biochemistry, 2007, 46, 3338-3355.	1.2	37
92	Application of Recombinant DNA Methods for Production of Cholinesterases as Organophosphate Antidotes and Detectors. Arhiv Za Higijenu Rada I Toksikologiju, 2007, 58, 339-345.	0.4	8
93	Mutation of acetylcholinesterase to enhance oxime-assisted catalytic turnover of methylphosphonates. Toxicology, 2007, 233, 79-84.	2.0	37
94	Structure-guided drug design: Conferring selectivity among neuronal nicotinic receptor and acetylcholine-binding protein subtypes. Biochemical Pharmacology, 2007, 74, 1164-1171.	2.0	42
95	Synaptic Arrangement of the Neuroligin/β-Neurexin Complex Revealed by X-Ray and Neutron Scattering. Structure, 2007, 15, 693-705.	1.6	64
96	Acetylcholinesterase: Converting a vulnerable target to a template for antidotes and detection of inhibitor exposure. Toxicology, 2007, 233, 70-78.	2.0	26
97	Gene Selection, Alternative Splicing, and Post-translational Processing Regulate Neuroligin Selectivity for β-Neurexinsâ€. Biochemistry, 2006, 45, 12816-12827.	1.2	117
98	Spectroscopic Analysis of Benzylidene Anabaseine Complexes with Acetylcholine Binding Proteins as Models for Ligandâ´'Nicotinic Receptor Interactions. Biochemistry, 2006, 45, 8894-8902.	1.2	45
99	Active site mutant acetylcholinesterase interactions with 2-PAM, HI-6, and DDVP. Biochemical and Biophysical Research Communications, 2006, 342, 973-978.	1.0	29
100	Structure and Function of Cholinesterases. , 2006, , 161-186.		23
101	Ligand-induced Conformational Changes in the Acetylcholine-binding Protein Analyzed by Hydrogen-Deuterium Exchange Mass Spectrometry. Journal of Biological Chemistry, 2006, 281, 12170-12177.	1.6	46
102	Influence of Agonists and Antagonists on the Segmental Motion of Residues near the Agonist Binding Pocket of the Acetylcholine-binding Protein. Journal of Biological Chemistry, 2006, 281, 39708-39718.	1.6	30
103	A Mutation Linked with Autism Reveals a Common Mechanism of Endoplasmic Reticulum Retention for the α,β-Hydrolase Fold Protein Family. Journal of Biological Chemistry, 2006, 281, 9667-9676.	1.6	53
104	α-Conotoxin OmIA Is a Potent Ligand for the Acetylcholine-binding Protein as Well as α3β2 and α7 Nicotinic Acetylcholine Receptors. Journal of Biological Chemistry, 2006, 281, 24678-24686.	1.6	51
105	Structural dynamics of the acetylcholine binding protein analyzed by timeâ€ŧesolved fluorescence anisotropy decay. FASEB Journal, 2006, 20, A244.	0.2	0
106	Structure – activity relationships and determinants of selectivity for congeners of the selective α7 partial agonist 3â€(2,4â€dimethoxybenzylidene)â€anabaseine (DMXBA or GTSâ€21) with the ACh binding protei (AChBPs). FASEB Journal, 2006, 20, A244.	ns0.2	0
107	Structural insights into competitive and nonâ€competitive nicotinic antagonists. FASEB Journal, 2006, 20, .	0.2	0
108	Crystal structure of a Cbtx–AChBP complex reveals essential interactions between snake α-neurotoxins and nicotinic receptors. EMBO Journal, 2005, 24, 1512-1522.	3.5	302

#	Article	IF	CITATIONS
109	Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations. EMBO Journal, 2005, 24, 3635-3646.	3.5	602
110	Acetylcholinesterase (AChE) gene modification in transgenic animals: Functional consequences of selected exon and regulatory region deletion. Chemico-Biological Interactions, 2005, 157-158, 79-86.	1.7	12
111	Agonist-mediated Conformational Changes in Acetylcholine-binding Protein Revealed by Simulation and Intrinsic Tryptophan Fluorescence. Journal of Biological Chemistry, 2005, 280, 8443-8451.	1.6	119
112	Structural Dynamics of the α-Neurotoxinâ^'Acetylcholine-Binding Protein Complex: Hydrodynamic and Fluorescence Anisotropy Decay Analysesâ€. Biochemistry, 2005, 44, 16602-16611.	1.2	13
113	The Arg451Cys-Neuroligin-3 Mutation Associated with Autism Reveals a Defect in Protein Processing. Journal of Neuroscience, 2004, 24, 4889-4893.	1.7	214
114	Acrylodan-conjugated Cysteine Side Chains Reveal Conformational State and Ligand Site Locations of the Acetylcholine-binding Protein. Journal of Biological Chemistry, 2004, 279, 28483-28491.	1.6	48
115	Structural and Ligand Recognition Characteristics of an Acetylcholine-binding Protein from Aplysia californica. Journal of Biological Chemistry, 2004, 279, 24197-24202.	1.6	136
116	Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel. Nature, 2004, 430, 896-900.	13.7	255
117	Contemporary paradigms for cholinergic ligand design guided by biological structure. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1875-1877.	1.0	2
118	Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1449-1454.	3.3	297
119	Mutant Cholinesterases Possessing Enhanced Capacity for Reactivation of Their Phosphonylated Conjugatesâ€. Biochemistry, 2004, 43, 3222-3229.	1.2	105
120	In Situ Click Chemistry:Â Enzyme Inhibitors Made to Their Own Specifications. Journal of the American Chemical Society, 2004, 126, 12809-12818.	6.6	395
121	Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site. EMBO Journal, 2003, 22, 1-12.	3.5	362
122	Curariform Antagonists Bind in Different Orientations to Acetylcholine-binding Protein. Journal of Biological Chemistry, 2003, 278, 23020-23026.	1.6	44
123	Nanosecond Dynamics of the Mouse Acetylcholinesterase Cys69–Cys96 Omega Loop. Journal of Biological Chemistry, 2003, 278, 30905-30911.	1.6	36
124	Acetylcholinesterase active centre and gorge conformations analysed by combinatorial mutations and enantiomeric phosphonates. Biochemical Journal, 2003, 373, 33-40.	1.7	108
125	STRUCTURE AND FUNCTION OF THE WAGLERINS, PEPTIDE TOXINS FROM THE VENOM OF WAGLER'S PIT VIPER, TROPIDOLAEMUS WAGLERI. Toxin Reviews, 2002, 21, 273-292.	1.5	6
126	Tryptophan Fluorescence Reveals Conformational Changes in the Acetylcholine Binding Protein. Journal of Biological Chemistry, 2002, 277, 41299-41302.	1.6	93

#	Article	IF	CITATIONS
127	Inhibitors of Different Structure Induce Distinguishing Conformations in the Omega Loop, Cys69–Cys96, of Mouse Acetylcholinesterase. Journal of Biological Chemistry, 2002, 277, 43301-43308.	1.6	28
128	Click Chemistry In Situ: Acetylcholinesterase as a Reaction Vessel for the Selective Assembly of a Femtomolar Inhibitor from an Array of Building Blocks. Angewandte Chemie - International Edition, 2002, 41, 1053-1057.	7.2	679
129	SPINAL NICOTINIC RECEPTOR ACTIVITY IN A GENETIC MODEL OF HYPERTENSION. Clinical and Experimental Hypertension, 2001, 23, 555-568.	0.5	7
130	Peripheral site ligands accelerate inhibition of acetylcholinesterase by neutral organophosphates. Journal of Applied Toxicology, 2001, 21, S13-S14.	1.4	16
131	Reversibly Bound and Covalently Attached Ligands Induce Conformational Changes in the Omega Loop, Cys69–Cys96, of Mouse Acetylcholinesterase. Journal of Biological Chemistry, 2001, 276, 42196-42204.	1.6	36
132	Interaction Kinetics of Reversible Inhibitors and Substrates with Acetylcholinesterase and Its Fasciculin 2 Complex. Journal of Biological Chemistry, 2001, 276, 4622-4633.	1.6	74
133	Mechanism of Oxime Reactivation of Acetylcholinesterase Analyzed by Chirality and Mutagenesisâ€. Biochemistry, 2000, 39, 5750-5757.	1.2	116
134	Subunit interface selective toxins as probes of nicotinic acetylcholine receptor structure. Pflugers Archiv European Journal of Physiology, 2000, 440, R115-R117.	1.3	8
135	Probing the Active Center Gorge of Acetylcholinesterase by Fluorophores Linked to Substituted Cysteines. Journal of Biological Chemistry, 2000, 275, 22401-22408.	1.6	25
136	Orientation of α-Neurotoxin at the Subunit Interfaces of the Nicotinic Acetylcholine Receptorâ€. Biochemistry, 2000, 39, 15388-15398.	1.2	35
137	Phosphoryl Oxime Inhibition of Acetylcholinesterase during Oxime Reactivation Is Prevented by Edrophonium. Biochemistry, 1999, 38, 9937-9947.	1.2	73
138	Crystal Structure of Mouse Acetylcholinesterase. Journal of Biological Chemistry, 1999, 274, 2963-2970.	1.6	117
139	Rapid binding of a cationic active site inhibitor to wild type and mutant mouse acetylcholinesterase: Brownian dynamics simulation including diffusion in the active site gorge. Biopolymers, 1998, 46, 465-474.	1.2	58
140	Electrostatic Influence on the Kinetics of Ligand Binding to Acetylcholinesterase. Journal of Biological Chemistry, 1997, 272, 23265-23277.	1.6	204
141	Nonidentity of the α-Neurotoxin Binding Sites on the Nicotinic Acetylcholine Receptor Revealed by Modification in α-Neurotoxin and Receptor Structures. Biochemistry, 1997, 36, 12836-12844.	1.2	44
142	Mutant acetylcholinesterases as potential detoxification agents for organophosphate poisoning. Biochemical Pharmacology, 1997, 54, 269-274.	2.0	48
143	Metrifonate. Drugs and Aging, 1997, 11, 497.	1.3	1
144	Aspartate 74 as a Primary Determinant in Acetylcholinesterase Governing Specificity to Cationic Organophosphonatesâ€. Biochemistry, 1996, 35, 10995-11004.	1.2	78

#	Article	IF	CITATIONS
145	Soluble monomeric acetylcholinesterase from mouse: Expression, purification, and crystallization in complex with fasciculin. Protein Science, 1996, 5, 672-679.	3.1	56
146	Acetylcholinesterase and Nicotinic Acetylcholine Receptor Expression Diverge in Muscular Dysgenic Mice Lacking the Lâ€Type Calcium Channel. Journal of Neurochemistry, 1996, 67, 111-118.	2.1	13
147	Spinal Nicotinic Receptor Expression in Spontaneously Hypertensive Rats. Hypertension, 1996, 28, 1093-1099.	1.3	19
148	Amino Acid Residues Controlling Reactivation of Organophosphonyl Conjugates of Acetylcholinesterase by Mono- and Bisquaternary Oximes. Journal of Biological Chemistry, 1995, 270, 6370-6380.	1.6	95
149	Specificity and Orientation of Trigonal Carboxyl Esters and Tetrahedral Alkylphosphonyl Esters in Cholinesterases. Biochemistry, 1995, 34, 11528-11536.	1.2	108
150	Acetylcholinesterase inhibition by fasciculin: Crystal structure of the complex. Cell, 1995, 83, 503-512.	13.5	357
151	Structural bases for the specificity of cholinesterase catalysis and inhibition. Toxicology Letters, 1995, 82-83, 453-458.	0.4	79
152	Theoretical analysis of the structure of the peptide fasciculin and its docking to acetylcholinesterase. Protein Science, 1995, 4, 703-715.	3.1	23
153	Epitope Mapping of Form-Specific and Nonspecific Antibodies to Acetylcholinesterase. Journal of Neurochemistry, 1993, 61, 2124-2132.	2.1	4
154	Structure and regulation of expression of the acetylcholinesterase gene. Chemico-Biological Interactions, 1993, 87, 199-207.	1.7	15
155	Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. Biochemistry, 1993, 32, 12074-12084.	1.2	437
156	Amino acid residues controlling acetylcholinesterase and butyrylcholinesterase specificity. Biochemistry, 1993, 32, 12-17.	1.2	314
157	Expression of recombinant acetylcholinesterase in a baculovirus system: kinetic properties of glutamate 199 mutants. Biochemistry, 1992, 31, 9760-9767.	1.2	143
158	Studies on the Topography of the Catalytic Site of Acetylcholinesterase Using Polyclonal and Monoclonal Antibodies. Journal of Neurochemistry, 1990, 55, 756-763.	2.1	24
159	Molecular cloning of mouse acetylcholinesterase: Tissue distribution of alternatively spliced mRNA species. Neuron, 1990, 5, 317-327.	3.8	174
160	Single gene encodes glycophospholipid-anchored and asymmetric acetylcholinesterase forms: Alternative coding exons contain inverted repeat sequences. Neuron, 1990, 4, 289-301.	3.8	105
161	Raman spectroscopic study on the conformation of 11 S form acetylcholinesterase fromTorpedo californica. FEBS Letters, 1987, 219, 202-206.	1.3	9
162	Primary structure of Torpedo californica acetylcholinesterase deduced from its cDNA sequence. Nature, 1986, 319, 407-409.	13.7	437

#	Article	IF	CITATIONS
163	Interaction of fluorescence probes with acetylcholinesterase. Site and specificity of propidium binding. Biochemistry, 1975, 14, 1989-1997.	1.2	360